Brief: Deciphera Pharmaceuticals Announces Completion Of Enrollment For Pivotal Phase 3 Motion Study Of Vimseltinib In Tgct
01/03/2023 13:15
Deciphera Pharmaceuticals Inc DCPH.O :
* DECIPHERA PHARMACEUTICALS ANNOUNCES COMPLETION OF
ENROLLMENT FOR
PIVOTAL PHASE 3 MOTION STUDY OF VIMSELTINIB IN TGCT
* DECIPHERA PHARMACEUTICALS INC - TOP-LINE RESULTS EXPECTED
IN Q4
OF 2023
Source text for Eikon: ID:nBw1JfdCba
Further company coverage: DCPH.O
Recent news on Deciphera Pharmaceuticals
See all newsBrief: Deciphera Pharmaceuticals Announces Oral Presentation Of Results From Phase 3 Study of Vimseltinib In Patients With Tenosynovial Giant Cell Tumor
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Deals of the day-Mergers and acquisitions